- জেনেরিক নাম
- Linagliptin + Metformin Hydrochloride
- শক্তি
- 2.5 mg + 500 mg
- ডোজ ফর্ম
- Tablet
- প্রস্তুতকারক
- One Pharma Ltd.
Lindela-M 2.5/500 Tablet Tablet
Lindela-M 2.5/500 Tablet সম্পর্কে
Lindela-M 2.5/500 Tablet হলো Linagliptin + Metformin Hydrochloride-এর একটি ব্র্যান্ড, শক্তি ২.৫ mg + ৫০০ mg, ট্যাবলেট আকারে। Linagliptin + Metformin Hydrochloride-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। এটি তৈরি করে One Pharma Ltd। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।
Linagliptin + Metformin Hydrochloride-এর ৩১টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Linatin M 2.5 mg + 500 mg Tablet-এর, প্রতি ইউনিট ৳ ৭.০০।
Lindela-M 2.5/500 Tablet কী?
Lindela-M 2.5/500 Tablet is a tablet from One Pharma Ltd., with the generic name Linagliptin + Metformin Hydrochloride. It contains linagliptin and metformin hydrochloride in a single tablet. Only a registered doctor can decide whether it suits a particular person, and the dose and course are set by the doctor. The dose and course are set by your doctor based on your needs.
Lindela-M 2.5/500 Tablet-এর ব্যবহার
It is added to a proper diet and exercise plan to improve blood sugar control when treatment with both linagliptin and metformin is considered appropriate. It is not a replacement for lifestyle measures. It is chosen when treatment with both linagliptin and metformin hydrochloride together is suitable for the person. Ask your doctor whether it is right for your condition.
Lindela-M 2.5/500 Tablet কীভাবে ব্যবহার করবেন
Swallow the tablet as directed. Lindela-M 2.5/500 Tablet is taken by mouth. Swallow the tablet with water. Swallow the tablet as your doctor or pharmacist advises. If you miss a dose, ask your doctor or pharmacist what to do. The dose and course are set by the doctor for each person, so follow the instructions given to you and do not change them yourself.
Lindela-M 2.5/500 Tablet-এর পার্শ্বপ্রতিক্রিয়া
The most common side effects reported with this combination are nasopharyngitis and diarrhea. Low blood sugar (hypoglycemia) is more common when it is taken with sulfonylureas. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor promptly if you suspect acute pancreatitis, which has been reported after marketing.
সতর্কতা ও নিরাপত্তা
This combination is not for everyone. There are no adequate studies of this combination in pregnant women, so it should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding. Your doctor may stop the medicine temporarily in these situations. Tell your doctor about kidney problems, surgery, contrast imaging or other medicines first.
সাধারণ প্রশ্ন
Why is Lindela-M 2.5/500 Tablet prescribed?
It is added to a proper diet and exercise plan to improve blood sugar control when treatment with both linagliptin and metformin is considered appropriate. It is not a replacement for lifestyle measures.
How do I use Lindela-M 2.5/500 Tablet correctly?
Swallow the tablet as directed. Lindela-M 2.5/500 Tablet is taken by mouth.
What are the side effects of Lindela-M 2.5/500 Tablet?
The most common side effects reported with this combination are nasopharyngitis and diarrhea. Low blood sugar (hypoglycemia) is more common when it is taken with sulfonylureas.
Is Lindela-M 2.5/500 Tablet safe for everyone?
This combination is not for everyone. There are no adequate studies of this combination in pregnant women, so it should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriateফার্মাকোলজি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.
মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.
In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.
Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.
Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.
Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.
In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.
In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.
5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination.P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of this medicine may be reduced when administered in combination.
প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Although Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Most common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.সতর্কতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
In a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
In the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable.During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions.
Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.
সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.বিকল্প ব্র্যান্ড: Linagliptin + Metformin Hydrochloride
একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
Linatin M Tablet
2.5 mg + 500 mg
Linagliptin + Metformin Hydrochloride
Delta Pharma Limited
৳ ৬.৮৬ ৳ ৭.০০ ২% ছাড় প্রতি ইউনিট
Linatin M Tablet
2.5 mg + 850 mg
Linagliptin + Metformin Hydrochloride
Delta Pharma Limited
৳ ৭.৮৪ ৳ ৮.০০ ২% ছাড় প্রতি ইউনিট
Adlinameg Tablet
2.5 mg+500 mg
Linagliptin + Metformin Hydrochloride
UniMed UniHealth
৳ ১১.৭৬ ৳ ১২.০০ ২% ছাড় প্রতি ইউনিট
Formet-L Tablet
2.5 mg + 500 mg
Linagliptin + Metformin Hydrochloride
Biopharma Ltd.
৳ ১১.৭৬ ৳ ১২.০০ ২% ছাড় প্রতি ইউনিট
Carlina-M Tablet
2.5 mg+500 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
৳ ১২.৭৪ ৳ ১৩.০০ ২% ছাড় প্রতি ইউনিট
Biolina Plus Tablet
2.5 mg+850 mg
Linagliptin + Metformin Hydrochloride
Biogen Pharmaceuticals Ltd.
৳ ১৩.২৩ ৳ ১৩.৫ ২% ছাড় প্রতি ইউনিট
Adlinameg Tablet
2.5 mg+850 mg
Linagliptin + Metformin Hydrochloride
UniMed UniHealth
৳ ১৩.৭২ ৳ ১৪.০০ ২% ছাড় প্রতি ইউনিট
Carlina-M Tablet
2.5 mg+850 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
৳ ১৩.৭২ ৳ ১৪.০০ ২% ছাড় প্রতি ইউনিট
Carlina-M Tablet
2.5 mg+1000 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
৳ ১৫.৬৮ ৳ ১৬.০০ ২% ছাড় প্রতি ইউনিট
Carlina-M 2.5/1000 Tablet
2.5 mg + 1000 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
৳ ১৫.৬৮ ৳ ১৬ ২% ছাড় প্রতি ইউনিট
Carlina-M 2.5/850 Tablet
2.5 mg + 850 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
দাম দেওয়া নেই
Carlina-M FC Tablet Tablet
2.5 mg + 500 mg
Linagliptin + Metformin Hydrochloride
Radiant Pharmaceuticals Ltd.
দাম দেওয়া নেই
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।